## Abstract ## BACKGROUND. The associations between passive smoking and the use of noncigarette tobacco products with pancreatic cancer are not clear. ## METHODS. In this case‐control study, the authors collected information on passive smoking and the use of noncigarette tobacco products in 808
Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer : A case-control study
✍ Scribed by Gabriele Capurso; Holger Schunemann; Gianfranco Delle Fave
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 37 KB
- Volume
- 112
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
W e read with interest the study by Hassan and colleagues 1 that evaluated a possible association between passive smoking and pancreatic cancer. The authors report that passive smoking is not a significant risk factor for pancreatic cancer, although it may increase the risk in smokers who are also exposed to passive smoking.
Although we congratulate the authors for their original research, we think that lack of data on the body mass index (BMI) among their considered confounding variables may somehow limit their conclusions.
Indeed, although these authors claim that results were adjusted for ''known risk factors,'' no data on body weight are discussed. Although older articles, especially retrospective ones, have reached inconsistent results, obesity is a well recognized risk factor for pancreatic cancer, with a 12% increased risk per 5 kg/m 2 BMI increase shown in a recent meta-analysis. 2 The mechanisms by which obesity increases pancreatic cancer risk are unclear, but a role for the insulin-IGF axis is likely.
Notably, in a cohort study on risk factors for pancreatic cancer, 3 obese smokers had a relative risk of 5.07 compared with 2.39 for nonobese smokers and with 1.87 for obese nonsmokers, suggesting a possible additional effect of BMI, which may be important for passive smoking also.
However, whereas the incidence of cancers mainly related to smoking, such as lung cancer, is overall decreasing in the US, possibly because of a reduction in smoking rates, that of pancreatic cancer is not.
In conclusion, we believe that greater attention should be paid to avoiding possible biases when analyzing the role of potentially preventable risk factors for pancreatic cancer. Therefore, we believe that health policies aimed at reducing the increasingly high prevalence of obesity in western countries may be very important. Recognition of obesity as a risk factor provides further rationale for such policies, and, thus, it should be included in evaluation of risk factors for pancreatic cancer in the future.
📜 SIMILAR VOLUMES
W e read with interest the study by Hassan and colleagues 1 that evaluated a possible association between passive smoking and pancreatic cancer. The authors report that passive smoking is not a significant risk factor for pancreatic cancer, although it may increase the risk in smokers who are also e
## Abstract Although tobacco smoking has long been recognized as a major risk factor for cancer of the upper aero‐digestive tract (UADT, __i.e__., oral cavity, pharynx, larynx, and oesophagus), very few studies have provided estimates of the effect of very low tobacco consumption. Step‐functions ha
## Abstract Genetic backgrounds may modify the association of environmental tobacco smoke (ETS) with lung cancer risk. Polymorphisms of both the activating and detoxifying enzymes, cytochrome P4501A1 (CYP1A1) and glutathione‐S‐transferase M1 (GSTM1), may be important as genetic factors. We conducte
## Abstract Cyclin D1 (CCND1) and E‐cadherin (CDH1) have been shown to be important genes of the β‐catenin/LEF pathway that is involved in colorectal carcinogenesis. However, epidemiological studies on relationship between genetic variants of these two genes and colorectal cancer (CRC) have shown i
## Abstract Vitamin D inhibits the development and growth of prostate cancer cells. Epidemiologic results on serum vitamin D levels and prostate cancer risk have, however, been inconsistent. We conducted a longitudinal nested case‐control study on Nordic men (Norway, Finland and Sweden) using serum